百利天恒38亿元定增圆满收官 发行价317元/股吸引18家机构参与

Core Viewpoint - Bailitianheng (688506) successfully completed its A-share private placement plan, raising a total of 3.764 billion yuan, aimed at accelerating the development of its innovative drug pipeline and enhancing its position among entry-level multinational corporations [1][2] Group 1: Fundraising Details - The private placement attracted participation from 18 well-known domestic and international institutions, with a subscription price set at 317 yuan per share [1] - The issuance price was determined to be 119.16% of the base price, which was set at 266.02 yuan per share [2] - The funds raised will be entirely allocated to innovative drug research and development projects, particularly focusing on the HIRE-ADC platform and GNC platform [2] Group 2: Clinical Trials and Product Pipeline - Bailitianheng is conducting 3 registration clinical trials in the U.S. for triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and urothelial carcinoma, with one indication included in the FDA's breakthrough therapy list [3] - In China, the company is running 11 Phase III clinical trials for various indications, with 5 indications recognized as breakthrough therapy by the CDE [3] - The company plans to commercialize its product iza-bren in China by 2026, with expectations for global market approval starting in 2029 [3] Group 3: Research and Development Investment - In the first half of 2025, Bailitianheng's R&D investment reached 1.039 billion yuan, a year-on-year increase of 90.74%, expanding its clinical pipeline to 15 drugs [3] - The private placement is a key initiative in the "Quality Improvement and Efficiency Recovery Action Plan" for 2025 [3]